We found that compared to normal tissue, USP32 expression was significantly elevated in 10 of 23 cancers, such as bladder thelial carcinoma (BLCA) and breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), stomach adenocarcinoma (STAD) and thyroid carcinoma (THCA) (Fig. 5B). This evidence concerns the gene USP32 and head and neck squamous cell carcinoma.